Myriad Genetics (MYGN) 24.98 -0.22

Myriad Genetics, Inc.
(MYGN) 24.98 -0.22

Last Trade:	24.98	Day Range:	24.88 - 25.19
Trade Time:	08:05PM	52wk Range:	17.51 - 27.00
Prev. Close:	25.20	Market Cap:	2.12B
Open:	25.00	Div Yield:	0
Volume:	644123	PE:	200
EPS:	1.26

The Latest On MYGN

UPDATE: Bank of America Initiates Coverage on Myriad Genetics 5/11/12 8:42am

Myriad and Cephalon Enter Into Companion Diagnostic Agreement 3/28/12 4:16pm

Notable Put Options Activity in Myriad Genetics 3/20/12 1:38pm

Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy 2/2/12 5:07pm

UPDATE: Auriga Raises Target on Myriad Genetics to $28 2/1/12 9:58am

Will Roche's Takeover Bid Help People Predict Diseases? 1/25/12 1:39pm

End-of-Day Market Summary for January 18, 2012 1/18/12 5:16pm

Myriad Genetics Acquires Exclusive Rights to RAD51C Gene 1/18/12 5:11pm

Auriga Maintains Buy Rating and $24 PT on Myriad Genetics 11/2/11 8:23am

Top 4 Stocks In The Research Services Industry With The Highest Operating Margin 11/1/11 4:09am

Benzinga's Top Upgrades 9/23/11 8:53am

Goldman Sachs Upgrades Myriad Genetics to Neutral 9/23/11 7:46am

UPDATE: Bank of America Initiates Coverage on Myriad Genetics 5/11/12

Myriad and Cephalon Enter Into Companion Diagnostic Agreement 3/28/12

Notable Put Options Activity in Myriad Genetics 3/20/12

Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy 2/2/12

UPDATE: Auriga Raises Target on Myriad Genetics to $28 2/1/12

Will Roche's Takeover Bid Help People Predict Diseases? 1/25/12

End-of-Day Market Summary for January 18, 2012 1/18/12

Myriad Genetics Acquires Exclusive Rights to RAD51C Gene 1/18/12

Auriga Maintains Buy Rating and $24 PT on Myriad Genetics 11/2/11

Top 4 Stocks In The Research Services Industry With The Highest Operating Margin 11/1/11

Benzinga's Top Upgrades 9/23/11

Goldman Sachs Upgrades Myriad Genetics to Neutral 9/23/11

Will Roche's Takeover Bid Help People Predict Diseases? 1/25/12

Top 4 Stocks In The Research Services Industry With The Highest Operating Margin 11/1/11

Top 4 Small-Cap Stocks In The Research Services Industry With The Highest Cash 6/29/11

Top 4 Stocks In The Research Services Industry With The Highest ROE (GPRO, MYGN, ACTG, FORR) 2/28/11

Puts Purchased on Myriad Genetics (MYGN) 1/31/11

Bulls Bet on Myriad Genetics (MYGN) 1/25/11

Calls Purchased on Myriad Genetics (MYGN) 1/24/11

Calls Purchased as Myriad Genetics Pops (MYGN) 1/12/11

ETFs For Biotech M&A Mania 12/6/10

Benzinga's Volume Movers (SIGA, AIXG, JOBS, MYGN) 10/13/10

MYGN Posts Decent FQ4 Despite Weaker Patient Office Visits 8/11/10

Afternoon Market Update (MYGN, LCC, UAUA, ALK) 8/11/10

UPDATE: Bank of America Initiates Coverage on Myriad Genetics 5/11/12

UPDATE: Auriga Raises Target on Myriad Genetics to $28 2/1/12

End-of-Day Market Summary for January 18, 2012 1/18/12

Auriga Maintains Buy Rating and $24 PT on Myriad Genetics 11/2/11

Benzinga's Top Upgrades 9/23/11

Goldman Sachs Upgrades Myriad Genetics to Neutral 9/23/11

Benzinga's Top Upgrades 9/12/11

UPDATE: Auriga Lowers PT on Myriad Genetics to $21 8/10/11

UPDATE: Goldman Sachs Reiterates Sell on Myriad Genetics, Reduces PT to $18 8/10/11

JP Morgan Reiterates Neutral and PT of $18 on Myriad Genetics 8/10/11

Goldman Sachs Lowers PT On Myriad Genetics To $18 8/10/11

Morgan Stanley Discontinuations 7/6 Continued 7/7/11

Trade MYGN
NOW!

Partner Headlines

Cepheid Expands European Portfolio - Analyst Blog 5/29/12

FDA Nod for Cepheid's Infinity-80 - Analyst Blog 5/25/12

Myriad in Research Partnership - Analyst Blog 5/22/12

Myriad Genetics 5/21/12

Myriad Reiterated Neutral - Analyst Blog 5/18/12

Myriad to Present Cancer Test Study - Analyst Blog 5/17/12

Cepheid Back to Neutral - Analyst Blog 5/14/12

Myriad Beats, Raises Guidance - Analyst Blog 5/2/12

Stocks Ease Off Session Highs 5/1/12

Stocks Headed For Mildly Higher Start 5/1/12

Qiagen Beats, Reiterates Outllook - Analyst Blog 4/27/12

Cepheid Incurs Loss as Costs Rise - Analyst Blog 4/20/12

Press Releases

Myriad Genetics to Present at Upcoming Investor Conferences in June 5/22/12 GlobeNewswire

Myriad Genetics Announces Presentation of Lung Cancer Study at American Society for Clinical Oncology Annual Meeting 5/16/12 GlobeNewswire

Myriad RBM Announces the Launch of Oncologymap® v. 2.0 5/10/12 PRWeb

Myriad Genetics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference 5/2/12 GlobeNewswire

Myriad Genetics Reports Record Third Fiscal Quarter 2012 Results 5/1/12 GlobeNewswire

Myriad Genetics to Announce Fiscal 2012 Third Quarter Results on Tuesday, May 1, 2012 4/10/12 GlobeNewswire

Myriad Study Finds High Prevalence of Mutations in the PMS2 Gene 3/29/12 GlobeNewswire

Myriad and Cephalon Enter Into Companion Diagnostic Agreement 3/28/12 GlobeNewswire

Supreme Court of the United States Remands Gene Patenting Case 3/26/12 GlobeNewswire

Prolaris(R) Test Awarded Best Poster Honor at 27th Annual EAU Congress in Paris, France 2/27/12 GlobeNewswire

Myriad's Prolaris(R) Test Shown to Significantly Predict Prostate Cancer Outcome in Needle Biopsy Tissue 2/24/12 GlobeNewswire

Myriad Genetics to Present at the Cowen and Company 32nd Annual Health Care Conference 2/22/12 GlobeNewswire

Get the latest MYGN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Myriad Genetics, Inc. stock price.

Myriad Genetics, Inc. by YCharts

Myriad Genetics (MYGN) 24.98 -0.22

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On MYGN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social